HelloBetter is a European leader in digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015 and headquartered in Berlin, HelloBetter has a strong evidence base with 33 randomized controlled trials published in peer‑reviewed journals. Several of its therapy programmes are listed as prescription digital therapeutics (DiGA) in Germany and available to tens of millions through standard care.

Its portfolio includes DiGAs and evidence‑based digital therapy programmes for conditions such as panic, insomnia and chronic pain. In 2022 HelloBetter launched HelloGina for the US market; in 2023 the company received Breakthrough Device Designation from the U.S. FDA for HelloBetter Panic. The company focuses on clinically supervised, research‑backed digital mental health solutions.

Headquarters: Berlin, Germany. Company size: ~51–200 employees. For current vacancies see the company's LinkedIn jobs page or their careers listings.